Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diclofenac-associated hepatotoxicity.

S M Helfgott1, J Sandberg-Cook, D Zakim

  • 1Beth Israel Hospital, Boston, Mass.

JAMA
|November 28, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and significance of automated history-taking software for clinical medicine, clinical research and basic medical science.

Journal of internal medicine·2016
Same author

A pilot study of social competence group training for adolescents with borderline intellectual functioning and emotional and behavioural problems (SCT-ABI).

Journal of intellectual disability research : JIDR·2011
Same author

Reductionism in medical science and practice.

QJM : monthly journal of the Association of Physicians·2010
Same author

Unusual digital sparing in rheumatoid arthritis a case of neuropsychoimmunologic involvement.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
Same author

Sensible approach to low back pain.

Bulletin on the rheumatic diseases·2002
Same author

Thermodynamics of fatty acid transfer.

The Journal of membrane biology·2000

Diclofenac sodium, a nonsteroidal anti-inflammatory drug (NSAID), has been linked to severe hepatitis and even death in some patients. Discontinuation of the drug is recommended if liver issues arise.

Area of Science:

  • Hepatology
  • Pharmacology
  • Clinical Medicine

Background:

  • Diclofenac sodium is a recently introduced phenylacetic acid-derived NSAID.
  • NSAIDs are widely used for their anti-inflammatory and analgesic properties.

Observation:

  • Seven patients developed significant hepatitis after initiating diclofenac sodium.
  • Hepatitis symptoms typically appeared within weeks of starting the drug and resolved after discontinuation.
  • One patient experienced recurrent hepatitis upon drug rechallenge, and another had fatal fulminant hepatitis.

Findings:

  • Diclofenac sodium use was associated with severe liver injury, including one fatality in the observed cases.
  • Three additional fatalities linked to diclofenac therapy were reported in European literature.

Related Experiment Videos

  • The comparative incidence of hepatotoxicity between diclofenac and other NSAIDs remains undetermined.

    • Implications:

    • Close monitoring of patients using diclofenac sodium for signs of liver disease is crucial.
    • Prompt drug cessation is advised upon detection of hepatic abnormalities.
    • Further research is needed to ascertain the comparative risk profile of diclofenac-induced hepatotoxicity.